Publications
Featured Publications
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Journal for ImmunoTherapy in Cancer (JITC)
November 2023
Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Society for Immunotherapy of Cancer (SITC)
November 2024
Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Society for Immunotherapy of Cancer (SITC)
November 2024
All Publications
A Phase 2 Clinical Trial of Nemvaleukin Alfa (ALKS 4230) Combined With Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): the ION-01 Trial
American Head & Neck Society (AHNS) International Conference
July 2021
Nemvaleukin Alfa Monotherapy in Patients With Advanced Melanoma: ARTISTRY-1
European Association of Dermato Oncology (EADO) Congress
April 2021
Phase 1/2 Study of Subcutaneously Administered ALKS 4230, a Novel Engineered Cytokine, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors: ARTISTRY-2
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2020
ALKS 4230: A Novel, Engineered Interleukin Variant Immunotherapy – Clinical Data Updates from ARTISTRY-1 Trial
European Society for Medical Oncology Virtual Congress 2020
September 2020
The Combination of a Mouse Ortholog of ALKS 4230, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, and the Angiogenesis Inhibitor Lucitanib Enhances Antitumor Activity
American Association for Cancer Research Annual Meeting
April 2020
Clinical Outcomes of Ovarian Cancer Patients Treated With ALKS 4230, a Novel Engineered Cytokine, in Combination With Pembrolizumab: ARTISTRY-1 Trial
Society for Immunotherapy of Cancer (SITC) Annual Meeting
April 2020
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
Journal for ImmunoTherapy of Cancer
March 2020
ARTISTRY-2: A Phase 1/2 Study of Subcutaneously Administrated ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2019
Intravenous Administration of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in a Phase 1/2 Study of Patients With Advanced Solid Tumors
American Society of Clinical Oncology (ASCO) Annual Meeting
May 2019
Peripheral Blood Lymphocyte Response to High Dose IL2 in RCC
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2018
Pharmacokinetics and Pharmacodynamic Effects of ALKS 4230, an Investigational Immunotherapeutic Agent, in Cynomolgus Monkeys After Intravenous and Subcutaneous Administration
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2018
Safety, Pharmacokinetics, and Pharmacodynamic Effects of ALKS 4230 in Patients With Advanced Solid Tumors From the Ongoing Dose Escalation Portion of a First In Human (FIH) Study
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2018